Cardiovascular effects of flavanol-rich chocolate in patients with heart failure

Andreas J Flammer1, Isabella Sudano, Mathias Wolfrum

  • 1Cardiovascular Center, Cardiology University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland.

European Heart Journal
|December 17, 2011
PubMed

Insights

Flavanol-rich chocolate (FRC) acutely improves vascular function in patients with congestive heart failure (CHF). Daily consumption over 4 weeks sustained these benefits, offering a potential alternative therapy for CHF patients.

Area of Science:

  • Cardiovascular Medicine
  • Nutritional Science
  • Clinical Research

Background:

  • Congestive heart failure (CHF) involves impaired endothelial function and heightened platelet reactivity.
  • Current therapies like statins are often ineffective in CHF patients.
  • Alternative treatments to improve cardiovascular function are clinically needed.

Purpose of the Study:

  • To investigate the potential of flavanol-rich chocolate (FRC) as an alternative therapy for improving cardiovascular function in CHF patients.
  • To assess the short-term and long-term effects of FRC on endothelial and platelet function in CHF.
  • To evaluate FRC's impact on nitric oxide bioavailability and oxidative stress.

Main Methods:

  • A double-blind, randomized placebo-controlled trial was conducted with 20 CHF patients.
  • Participants consumed either FRC or control chocolate (CC) for 4 weeks (two bars/day).
  • Endothelial function was measured by brachial artery flow-mediated vasodilatation; platelet function was assessed via adhesion.

Main Results:

  • FRC significantly improved endothelial function acutely (2 hours post-ingestion) and after 4 weeks of daily consumption.
  • Platelet adhesion was significantly reduced 2 hours after FRC intake, but this effect was not sustained.
  • Control chocolate (CC) showed no significant effects on endothelial or platelet function.

Conclusions:

  • Flavanol-rich chocolate (FRC) demonstrates acute and sustained benefits for vascular function in CHF patients.
  • Daily FRC intake over 4 weeks improved endothelial function, even after 12 hours of abstinence.
  • FRC also exhibited an inhibitory effect on platelet function, suggesting a dual therapeutic benefit for CHF.
Abstract

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...